Early postoperative growth hormone measurement as a predictive marker for acromegaly remission

IF 3.3 4区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ivana Kraljevic, Mirsala Solak, Diana Kovac, Tanja Skoric Polovina, Karin Zibar Tomsic, Annemarie Balasko, Tina Dusek, Darko Kastelan
{"title":"Early postoperative growth hormone measurement as a predictive marker for acromegaly remission","authors":"Ivana Kraljevic,&nbsp;Mirsala Solak,&nbsp;Diana Kovac,&nbsp;Tanja Skoric Polovina,&nbsp;Karin Zibar Tomsic,&nbsp;Annemarie Balasko,&nbsp;Tina Dusek,&nbsp;Darko Kastelan","doi":"10.1111/jne.13434","DOIUrl":null,"url":null,"abstract":"<p>Growth hormone (GH) has a short half-life and declines abruptly following somatotropinoma surgery, enabling its prompt measurement as an indicator of surgical success. This study assesses the predictive value of early postoperative GH levels for 3-month and &gt;1-year remission of acromegaly. We conducted a retrospective search in our database of patients who had undergone transsphenoidal surgery of GH-secreting pituitary adenoma from January 2011 to June 2022. Only the patients who underwent the first pituitary surgery and had GH measurements on the fifth postoperative day were included. The 3-month and &gt;1-year remission of acromegaly was defined as achieving the GH nadir of &lt;0.4 μg/L during an oral glucose tolerance test and maintaining normal insulin-like growth factor 1 levels at the initial follow-up visit 3 months after surgery and throughout at least the first year postoperation. We included 63 patients in the analysis, with a median follow-up of 51.8 (13–155) months. The 3-month remission was achieved in 42 (66.7%) patients, and &gt;1-year remission without additional therapy in 38 (60.3%) patients. Those who achieved &gt;1-year remission had significantly lower fifth-day postoperative GH levels (0.59 [0.09–8.92] vs. 2.63 [0.25–24.64] μg/L, <i>p</i> &lt; .001). Receiver-operating characteristic analysis revealed a significant value of fifth-day postoperative GH levels regarding the prediction of 3-month (area under the curve [AUC], 0.834; <i>p</i> &lt; .0001) and &gt;1-year (AUC, 0.783; <i>p</i> &lt; .0001) acromegaly remission. The GH threshold of ≤1.57 μg/L yielded a sensitivity of 90.5% and a specificity of 71.4% at 3 months and 89.5% sensitivity and 60% specificity at the &gt;1-year remission, respectively. Notably, all patients with fifth-day postoperative GH levels ≤0.23 μg/L exhibited remission of acromegaly throughout the follow-up period. Early postoperative GH measurement could be a reliable predictor of both 3-month and &gt;1-year remission of acromegaly.</p>","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.13434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Growth hormone (GH) has a short half-life and declines abruptly following somatotropinoma surgery, enabling its prompt measurement as an indicator of surgical success. This study assesses the predictive value of early postoperative GH levels for 3-month and >1-year remission of acromegaly. We conducted a retrospective search in our database of patients who had undergone transsphenoidal surgery of GH-secreting pituitary adenoma from January 2011 to June 2022. Only the patients who underwent the first pituitary surgery and had GH measurements on the fifth postoperative day were included. The 3-month and >1-year remission of acromegaly was defined as achieving the GH nadir of <0.4 μg/L during an oral glucose tolerance test and maintaining normal insulin-like growth factor 1 levels at the initial follow-up visit 3 months after surgery and throughout at least the first year postoperation. We included 63 patients in the analysis, with a median follow-up of 51.8 (13–155) months. The 3-month remission was achieved in 42 (66.7%) patients, and >1-year remission without additional therapy in 38 (60.3%) patients. Those who achieved >1-year remission had significantly lower fifth-day postoperative GH levels (0.59 [0.09–8.92] vs. 2.63 [0.25–24.64] μg/L, p < .001). Receiver-operating characteristic analysis revealed a significant value of fifth-day postoperative GH levels regarding the prediction of 3-month (area under the curve [AUC], 0.834; p < .0001) and >1-year (AUC, 0.783; p < .0001) acromegaly remission. The GH threshold of ≤1.57 μg/L yielded a sensitivity of 90.5% and a specificity of 71.4% at 3 months and 89.5% sensitivity and 60% specificity at the >1-year remission, respectively. Notably, all patients with fifth-day postoperative GH levels ≤0.23 μg/L exhibited remission of acromegaly throughout the follow-up period. Early postoperative GH measurement could be a reliable predictor of both 3-month and >1-year remission of acromegaly.

术后早期生长激素测量作为肢端肥大症缓解的预测指标。
生长激素(GH)的半衰期很短,在嗜体细胞瘤手术后会突然下降,因此及时测量生长激素可作为手术成功与否的指标。本研究评估了术后早期 GH 水平对肢端肥大症 3 个月和 1 年以上缓解的预测价值。我们在数据库中对2011年1月至2022年6月期间接受经蝶窦手术治疗分泌GH垂体腺瘤的患者进行了回顾性检索。只有首次接受垂体手术并在术后第五天测量过 GH 的患者才被纳入其中。38例(60.3%)患者的肢端肥大症3个月和>1年缓解被定义为无需额外治疗即可达到1年缓解的GH最低值。术后第五天 GH 水平明显降低(0.59 [0.09-8.92] vs. 2.63 [0.25-24.64] μg/L,p 1 年,AUC,0.783;p 1 年缓解,分别为 0.59 [0.09-8.92] vs. 2.63 [0.25-24.64] μg/L,p 1 年)。值得注意的是,所有术后第五天 GH 水平≤0.23 μg/L 的患者在整个随访期间的肢端肥大症都得到了缓解。术后早期 GH 测量结果可以可靠地预测肢端肥大症 3 个月和 1 年后的缓解情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuroendocrinology
Journal of Neuroendocrinology 医学-内分泌学与代谢
CiteScore
6.40
自引率
6.20%
发文量
137
审稿时长
4-8 weeks
期刊介绍: Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信